Cryoport Reports 14% Revenue Growth in Q2 2025 Earnings

Cryoport (CYRX) reported a 14% increase in total revenue for Q2 2025, driven by growth in both services and products. Service revenue grew by 21%, and commercial cell and gene therapy revenue rose 33%, indicating strong demand for its offerings. The company also saw improvements in gross margin and profitability metrics.

By Motley Fool Transcribing · Motley Fool · May 4, 2026, 20:09 UTC

Cryoport Reports 14% Revenue Growth in Q2 2025 Earnings

Tickers: $CYRX

Topics: Cryoport Earnings Report Financial Performance Margin Improvement Revenue Growth

Read the full article at Motley Fool

More World news

Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC